The company said revenues for the quarter and full-year 2016 included sales of Olerup HLA typing products, which CareDx got through its acquisition of Allenex.
A startup company is betting that CRISPR could be used to enable xenotransplantation from pigs to humans, Technology Review reports.
The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.
The firm saw a 6 percent boost year over year in test volumes for its AlloMap non-invasive blood test for heart transplant patients.
Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for the monitoring of transplanted organ rejection.
A team led by Stanford's Mike Snyder is collaborating with investigators from the International Genetics & Translational Research in Transplantation Network (iGeneTrain) consortium.
The company had previously said it intended to use the proceeds to continue its development of its solid organ transplant diagnostic AlloSure.
The company said it achieved record volumes for its AlloMap non-invasive blood test for heart transplant patients.
The partners will work together to see whether cell-free DNA levels can be used to predict organ injury in kidney transplantation and improve clinical outcomes.
The collaboration will use Transplant Genomics' TruGraf test for post-kidney transplant monitoring to try to personalize immunosuppression therapies.
Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.
People around the globe took to the streets to support science — some with signs.
Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.
In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.